Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,767 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Branch II Clear all

Conditions: Cerebral Palsy Infantile, Disabilities Multiple, Pain
Interventions: PediQUEST ResPOND; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Transitional Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab; Other · Drug · Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Lung Carcinoma
Interventions: Fluorescein, Image-Guided Needle Confocal Laser Endomicroscopy, Ultrasound-Guided Transbronchial Needle Aspiration; Other · Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
Interventions: pTVG-HP, pTVG-AR, Pembrolizumab; Biological · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: St Louis, Missouri • Madison, Wisconsin

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Aerobic Exercise, Exercise Intervention, Educational Intervention, Dual X-ray Absorptiometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing, Physical Performance Testing, Questionnaire Administration, Biospecimen Collection, Pulmonary Function Test; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions: Teclistamab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Irene Ghobrial, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 3
States / cities: Denver, Colorado • Boston, Massachusetts • Portland, Oregon

Conditions: Breast Cancer, Depression, Fatigue
Interventions: Bio-field energy therapy, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment, therapeutic touch; Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: dasatinib, lapatinib ditosylate, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Cabozantinib, Everolimus, Lenvatinib, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas • Charlottesville, Virginia

Conditions: Lung Cancer
Interventions: Allogeneic B7.1/HLA-A1, Placebo; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Conditions: Small Cell Lung Cancer
Interventions: DS-3201b, irinotecan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 25
States / cities: Scottsdale, Arizona • Palo Alto, California • Santa Monica, California + 21 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder
Interventions: memantine hydrochloride, placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Nausea and Vomiting, Pancreatic Cancer, Primary Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: palonosetron hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 69
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more

Conditions: Gestational Diabetes Mellitus
Interventions: Hola Bebe; Behavioral
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Cambridge, Massachusetts • Jamaica Plain, Massachusetts • Lynn, Massachusetts

Conditions: Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions: Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions: Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Solid Tumor
Interventions: Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: Glioblastoma
Interventions: ONC201; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions: Abiraterone Acetate, Laboratory Biomarker Analysis, Prednisone, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • South Pasadena, California + 10 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BIO 300 Oral Suspension, Paclitaxel, Carboplatin, Radiotherapy; Drug · Radiation
Lead sponsor: Humanetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Detroit, Michigan • Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: soy protein isolate, placebo; Dietary Supplement · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
Interventions: Best Practice, Exercise Intervention, App-Based Intervention, Interview, Wearable Activity Tracker, Physical Performance Testing, Questionnaire Administration; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

The PediQUEST Response to Pain Of Children With Neurologic Disability Pilot Randomized Controlled Trial

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Needle-Based Confocal Laser Endomicroscopy for Diagnosis of Lung Cancer in Patients With Peripheral Pulmonary Nodules

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Mobile Health App to Reduce Diabetes in Latina Women With Prior Gestational Diabetes II

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

BIO 300 Non-Small Cell Lung Cancer Study

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial